Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H & Thisted, R K 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet. Infectious diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Johansen, I S & Larsen, L 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet Infectious Diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 The Lancet. Infectious Diseases